Author: Lee, Su Jeen; Park, Hyoâ€Jung; Ko, Hae Li; Lee, Jung Eun; Lee, Hyun Joo; Kim, Hun; Nam, Jaeâ€Hwan
                    Title: Evaluation of glycoprotein E subunit and live attenuated varicellaâ€zoster virus vaccines formulated with a singleâ€strand RNAâ€based adjuvant  Cord-id: qek9jy2c  Document date: 2020_3_13
                    ID: qek9jy2c
                    
                    Snippet: INTRODUCTION: Varicellaâ€zoster virus (VZV), a human alphaherpesvirus 3, elicits both chickenpox and shingles and/or postherpetic neuralgia. A live attenuated vaccine (LAV) and glycoprotein E (gE) subunit vaccine were developed to prevent VZVâ€induced diseases. We recently reported that singleâ€strand RNA (ssRNA) based on the intergenic region of the internal ribosome entry site of cricket paralysis virus (CrPV) is an effective adjuvant for proteinâ€based and virusâ€like particleâ€based va
                    
                    
                    
                     
                    
                    
                    
                    
                        
                            
                                Document: INTRODUCTION: Varicellaâ€zoster virus (VZV), a human alphaherpesvirus 3, elicits both chickenpox and shingles and/or postherpetic neuralgia. A live attenuated vaccine (LAV) and glycoprotein E (gE) subunit vaccine were developed to prevent VZVâ€induced diseases. We recently reported that singleâ€strand RNA (ssRNA) based on the intergenic region of the internal ribosome entry site of cricket paralysis virus (CrPV) is an effective adjuvant for proteinâ€based and virusâ€like particleâ€based vaccines. Here, Chinese hamster ovary expression system and an LAV from Oka/SK strains. METHODS: We appraised the adjuvant effect of the same CrPV ssRNA encoding the gE gene formulated in the two vaccines using VZVâ€primed C57BL/6 mice and guinea pigs. Humoral immunity and cellâ€mediated immunity were assessed by enzymeâ€linked immunosorbent assay (ELISA) and ELISPOT in gE subunit vaccine and by ELISA and fluorescent antibody to membrane antigen in LAV. RESULTS: The gE subunit vaccineâ€induced gEâ€specific antibodies and CD4(+) Tâ€cell responses (indicated by interferonâ€Î³ [IFNâ€Î³] and interleukinâ€2 secretion) in the ssRNAâ€based adjuvant containing the VZV gE gene. Therefore, an ssRNA adjuvant combined with gE antigen can trigger the innate immune response and induce an adaptive immune response to ultimately activate humoral and cellâ€mediated responses. VZV LAV could also induce VZVâ€specific antibodies and IFNâ€Î³ stimulated by LAV, whereas the effect of ssRNA as a vaccine adjuvant could not be confirmed. However, the ssRNA adjuvant increased VZVâ€specific neutralizing antibody response. CONCLUSIONS: Taken together, these results highlight that the gE subunit vaccine and LAV developed in this study can be functional VZV vaccines, and ssRNAs appear to function better as adjuvants in a subunit vaccine than in an LAV.
 
  Search related documents: 
                                Co phrase  search for related documents- adaptive immune response and adjuvant effect: 1
- adaptive immune response and adjuvant enhance: 1, 2, 3, 4
- adaptive immune response and adjuvant induce: 1
 
                                Co phrase  search for related documents, hyperlinks ordered by date